AB0612
INFRINGEMENT OF THE BLOOD LIPID SPECTRUM IN CHILDREN AND ADOLESCENTS WITH SLE AND THEIR PREDICTIVE VALUE FOR THE FURTHER COURSE OF THE DISEASE

N.S. Shevechenko1,2, L.F. Bogmat3, I.M. Bessonova2,3, V.V. Nikonorov2
1department of pediatrics No2, V. N. Karazin Kharkiv National University;
2department of cardiorheumatology, Institute of Children and Adolescents Health Care;
3department of pediatrics, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine

Background: Infringements of the lipid blood spectrum, or so-called dyslipidemia, are common in adults suffering from SLE and ranges from 36% to 60%.1 Many researchers confirmed the accelerated development of atherosclerosis among patients and high risk of epy cardiovascular complications with deterioration of life expectancy. However, the role of prolonged storage of dyslipidemia and subclinical signs of hypercoagulability on the course of the disease is unspecific.

Objectives: The aim of the study was to clarify the prognostic importance of the role of storage of metabolic shifts in children with SLE on the background of treatment for the course of the disease.

Methods: A total of 35 people aged 7–18 years with SLE who were ill for more than one year and received complex therapy with glucocorticoids and immunosuppressive drugs were examined. The average age of the patients was 173.56 ±14.17 months; the total duration of the disease was 48.45 ±3.18 months. General clinical trials included the complex included autoantibodies, disease activity, drugs. Total cholesterol (TCh), triglycerides (TG), high density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, ApoA-I and lipoprotein-a were evaluated. The state of the blood coagulation system was also studied: fibrinogen of the blood, prothrombin index, thrombin time, active partial thrombin time, d-dimer, international normalized ratio.

Results: The presence of atroheartic dislipoproteinemia in 60.0% of ill children and adolescents on SLE in children and adolescents, disorders in the system of hemostasis in 25.0% was established.

As a result of a multiple regression analysis with step-by-step exclusion of minor variables, serum creatinine serum levels in patients with SLE depend on the level of TG of blood with high predictive accuracy: blood creatinine=−0.0672884 +0.0127034 * TG; R2=62.4% (p<0.05).

A multivariable regression analysis also proved that the level of circulating immune complexes in patients with SIV significantly depends on the level of total cholesterol, complement and TG by the formula: CIC=1.44278 +0.188976 * TCh +1.51503 * complement +0.35538 * TG; R=94.25%; R2=90.02%; p<0.01.

The mean indices of state of the blood coagulation system indices for children and adolescents on the background of SLE with the duration of the disease for more than one year. They are not only a risk factor for atherosclerotic lesions; they are also a factor in maintaining the activity of the disease and the development of sustained kidney damage.

References:


Disclosure of Interest: None declared

AB0614
THE LUPUS STUDIES: THE EUROPEAN AND SPANISH POINT OF VIEW

N. Bahamonges-Rosa1, A. Muñoz Jiménez2, F.J. Hidalgo3, M.V. Pardo3, J.I. Diago Cabezudo1
1GSK, Madrid; 2Hospital Virgen del Rocio, Sevilla, Spain

Background: Improving systemic lupus erythematosus patient care comes from the advances performed first in basic science that improved our understanding of the mechanism underlying the pathogenesis and finding effective and safe medications that led to treatment improvement. Furthermore, clinical trials play a key role in advancing both our medical knowledge of the disease and novel treatments.

Objectives: This work aims to offer an overview of the type and characteristics of lupus studies and to analyse the contribution that Europe and Spain have made in supporting those investigations.

Methods: A systematic review of the public registry database of publicly and privately supported clinical studies (CS), ClinicalTrials.gov, was done considering “lupus” as a search criteria (database generated with all CS registered on the 19th September 2017). Data collected included: CT code, title, sponsor, countries participating, study phase, condition and intervention.

Results: Study distribution. By 19th September 2017 there were a total of 256127 CS registered in the world, from which 611 (0.24%) are associated with lupus studies. From those, 27.2% are carried out in Europe. Spain is the third country in Europe in number of lupus CS after France and Germany.

Type and distribution of the studies. In the generated clinicaltrials.gov data base, the studies are associated to a type of study. The distribution varies depending on the geographical area. In general, the main type of lupus studies conducted in the world are related to the discovery and development of new treatments (n=406) but there are also behavioural, devices investigation, diagnostic test, dietary supplementation, genetic and radiation studies. In Spain, 94.6% of the studies registered are related to new treatment development.

The distribution of the lupus studies are as follows: Financial support. 56.6% of all studies are funded by sources other than industry and 34.8% are supported by it. In a detailed analysis, 12.5% of the studies are under the economic support of the National Institutes of Health (NIH) or the partnership of NIH-other partners. The scenario is different in Europe where industry supported 54.8% of the studies and in Spain where industry supported 87.3% of the studies. Moreover, the funding profile in Spain showed that 92.3% of the studies associated with new treatments are supported by industry and 7.7% of them are supported by other sources. On the other hand, 100% of the studies not related with...